SINGAPORE MEDICAL GROUP LIMITED
(Company Registration No.: 200503187W)

RESPONSE TO SGX QUERIES REGARDING TRADING ACTIVITY

The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Company**" or "**SMG**", and together with its subsidiaries, the "**Group**") refers to the queries from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 29 July 2016 regarding the unusual price and volume movements in the Company's shares and wishes to respond to the queries as follows:

Question 1:

Are you (the issuer) aware of any information not previously announced concerning you, your subsidiaries or associated companies which, if known, might explain the trading? Such information may include events that are potentially material and price-sensitive, such as discussions and negotiations that may lead to joint ventures, mergers, acquisitions or purchase or sale of a significant asset. You may refer to paragraph 9 in Appendix 7A of the Catalist Rules for further examples.
- If yes, the information shall be announced immediately.

The Company's Response

The Company is currently in the process of finalising its financial statements for the 6-month period ended 30 June 2016 which will be announced no later than 14 August 2016.

The Company constantly reviews options and explores opportunities to enhance shareholders' value as part of the Group's strategy. As at the date of this announcement, the Company has been in confidential discussions with various parties on a possible investment opportunity. No definitive agreement has been entered into and accordingly, there is no assurance or certainty that the transaction will materialise. Further announcement will be made by the Company via SGXNET if and when definitive agreement is reached.

Save for the above, the Company is not aware of any information not previously announced concerning the Company, its subsidiaries or associated companies which, if known, might explain the trading.

Question 2:

Are you aware of any other possible explanation for the trading? Such information may include public circulation of information by rumours or reports.

The Company's Response

Saved for the response to Question 1 above, the Company is not aware of any other possible explanation for the trading activity on 29 July 2016.

Question 3:

Can you confirm your compliance with the listing rules and, in particular, Catalist Rule 703?

The Company's Response

The Company confirms that it is in compliance with the listing rules of the SGX-ST Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**"), and in particular, Catalist Rule 703 regarding disclosure of material information, and will, in compliance with the applicable Catalist Rules, make further announcement to update its shareholders on the matter as and when appropriate.

The Board collectively and individually takes responsibility for the accuracy of the aforesaid replies to the queries raised by the SGX-ST.

By Order of the Board
Dr Beng Teck Liang
Executive Director and Chief Executive Officer
29 July 2016

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the relevant rules of the SGX-ST, this being the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not independently verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01 Singapore Land Tower Singapore 048623, Telephone: +65 6337 5115.